The natural history of chronic airflow obstruction
- PMID: 871704
- PMCID: PMC1607732
- DOI: 10.1136/bmj.1.6077.1645
The natural history of chronic airflow obstruction
Abstract
A prospective epidemiological study of the early stages of the development of chronic obstructive pulmonary disease was performed on London working men. The findings showed that forced expiratory volume in one second (FEV1) falls gradually over a lifetime, but in most non-smokers and many smokers clinically significant airflow obstruction never develops. In susceptible people, however, smoking causes irreversible obstructive changes. If a susceptible smoker stops smoking he will not recover his lung function, but the average further rates of loss of FEV1 will revert to normal. Therefore, severe or fatal obstructive lung disease could be prevented by screening smokers' lung function in early middle age if those with reduced function could be induced to stop smoking. Infective processes and chronic mucus hypersecretion do not cause chronic airflow obstruction to progress more rapidly. There are thus two largely unrelated disease processes, chronic airflow obstruction and the hypersecretory disorder (including infective processes).
Similar articles
-
Epidemiology of bronchial hypersecretion: recent studies.Eur J Respir Dis Suppl. 1987;153:13-8. Eur J Respir Dis Suppl. 1987. PMID: 3322856 Review.
-
Relevance of airflow obstruction and mucus hypersecretion to mortality.Respir Med. 1991 Jan;85(1):27-35. doi: 10.1016/s0954-6111(06)80207-6. Respir Med. 1991. PMID: 2014356
-
Pulmonary Artery Abnormalities in Ex-smokers with and without Airflow Obstruction.COPD. 2016;13(2):224-34. doi: 10.3109/15412555.2015.1074666. Epub 2015 Nov 25. COPD. 2016. PMID: 26606693
-
Prevalence of airflow obstruction in smokers and never-smokers in Switzerland.Eur Respir J. 2010 Dec;36(6):1259-69. doi: 10.1183/09031936.00004110. Epub 2010 Apr 22. Eur Respir J. 2010. PMID: 20413537
-
Chronic obstructive pulmonary disease with mild airflow limitation: current knowledge and proposal for future research - a consensus document from six scientific societies.Int J Chron Obstruct Pulmon Dis. 2017 Aug 29;12:2593-2610. doi: 10.2147/COPD.S132236. eCollection 2017. Int J Chron Obstruct Pulmon Dis. 2017. PMID: 28919728 Free PMC article. Review.
Cited by
-
Tobacco smoke induced COPD/emphysema in the animal model-are we all on the same page?Front Physiol. 2013 May 15;4:91. doi: 10.3389/fphys.2013.00091. eCollection 2013. Front Physiol. 2013. PMID: 23720629 Free PMC article.
-
Estimating rate of lung function change using clinical spirometry data.BMJ Open Respir Res. 2024 Oct 3;11(1):e001896. doi: 10.1136/bmjresp-2023-001896. BMJ Open Respir Res. 2024. PMID: 39362797 Free PMC article.
-
Systemic inflammation in COPD in relation to smoking status.Multidiscip Respir Med. 2011 Aug 31;6(4):214-9. doi: 10.1186/2049-6958-6-4-214. Multidiscip Respir Med. 2011. PMID: 22958407 Free PMC article.
-
The Lung Immune Response to Nontypeable Haemophilus influenzae (Lung Immunity to NTHi).J Immunol Res. 2015;2015:706376. doi: 10.1155/2015/706376. Epub 2015 May 31. J Immunol Res. 2015. PMID: 26114124 Free PMC article. Review.
-
Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy.Respir Res. 2015 Feb 15;16(1):25. doi: 10.1186/s12931-015-0184-8. Respir Res. 2015. PMID: 25849223 Free PMC article. Review.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources